---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000007"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:31:47.862483+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novocure reports Q4 net loss $47.1M, full year revenue down 5%; NSCLC PMA accepted

## Summary
- Full year 2023 net revenues $509.3M, down 5% YoY; Q4 net revenues $133.8M, up 4% YoY.
- Q4 net loss $47.1M ($0.45 loss per share); adjusted EBITDA -$31.6M.
- Active patients 3,755 (+9% YoY); prescriptions 1,564 (+14% YoY).
- FDA accepted PMA for TTFields in NSCLC; enrollment completed in phase 3 TRIDENT trial.
- Cash, cash equivalents and short-term investments $910.6M as of Dec 31, 2023.

## SEC filing metadata
- accession: 0001645113-24-000007
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/nvcr-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000007
- JSON: https://secwatch.observer/filing/0001645113-24-000007.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000007.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported the fiscal year ended December 31, 2023 results: revenue $509.3 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $509.3 million
  - Result: reported results
  source text: Total net revenues for the year were $509.3 million, a decrease of 5% year-over-year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm
- Earnings Releases
  NovoCure Ltd reported the quarter ended December 31, 2023 results: revenue $133.8 million, net income Net loss for the quarter was $47.1 million, EPS loss per share of $0.45.
  - Period: the quarter ended December 31, 2023
  - Revenue: $133.8 million
  - Net income: Net loss for the quarter was $47.1 million
  - EPS: loss per share of $0.45
  - Result: reported results
  source text: Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.